jelfa omnadren

Symbicort contains formoterol and budesonide, which jelfa omnadren have different mechanisms of action and show additive effect in reducing the frequency of exacerbations of asthma.
The special properties of budesonide and formoterol allow you to use a combination of both as maintenance therapy and cupping, or as a maintenance treatment of asthma . budesonide .

Glucocorticosteroid which after inhalation provides rapid (within hours) and the dose dependent anti-inflammatory effect on the airways, reducing the frequency and severity of symptoms of asthma exacerbations. In the appointment of inhaled budesonide observed lower incidence of serious adverse effects than with systemic glucocorticosteroids. It reduces the severity of edema of the bronchial mucosa, mucus production, education, sputum and airway hyperresponsiveness. The exact mechanism of anti-inflammatory effect of glucocorticosteroids is unknown. Formoterol . Formoterol – selective agonist  adrenergic receptor, which upon inhalation is a rapid and prolonged airway smooth muscle relaxation in patients with reversible obstruction of the airways. Dose-dependent bronchodilator effect occurs within 1-3 minutes after inhalation and lasts for at least 12 hours after administration of a single dose.

Symbicort Turbuhaler: budesonide + formoterol Asthma Clinical efficacy of Symbicort as maintenance therapy

. The addition of formoterol to budesonide reduces the severity of asthma symptoms, improve lung function and reduce the frequency of exacerbations
Action Symbicort turbuhaler lung function corresponds to the action of the combination of monotherapies budesonide and formoterol, and exceeded the action one of budesonide. In all cases, cupping used beta2-agonists of short action. There was no decrease in anti-asthmatic effect over time. The drug is well tolerated.
Turbuhaler Symbicort as maintenance therapy in combination with beta2-agonists short action for relief of attacks was administered to patients aged 6 to 11 years for 12 weeks (two inhalations of 80 / 4.5 micrograms / inhalation twice day). Were marked improvement in pulmonary function and good tolerability as compared to the corresponding dose of budesonide turbuhaler.

Clinical efficacy of Symbicort as maintenance therapy and cupping. During the observation of the jelfa omnadrenpatients treated with Symbicort therapy as maintenance therapy and cupping a period of 6 to 12 months, there was a statistically and clinically significant reduction in the number of severe exacerbations, increasing the amount of time before the onset of the first exacerbation compared to the combination of budesonide or Symbicort as maintenance therapy and beta2-agonists for relief of attacks. Also notes the effective control of the symptoms of the disease, pulmonary function and decrease the frequency of inhalation destination for cupping. There was no development of tolerance to the prescribed therapy. For patients seeking medical treatment in connection with the development of an acute attack of asthma after inhalation  symptom relief (removal of bronchospasm) occurred as rapidly and efficiently as after administration of salbutamol and formoterol.

Chronic obstructive pulmonary disease (COPD)  in patients receiving jelfa omnadren turbuhaler there was a significant reduction in the rate of exacerbations compared with patients receiving therapy just as formoterol or placebo (mean rate of exacerbations compared with 1,4 1,8 1.9 in the placebo / formoterol group). There was no difference between the reception and Symbicort Formoterol to measure forced expiratory volume in one second (FEV 1 ).